Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Alvocidib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 known ✓ | P24941 | 14/20 | 1.00 |
| ▸ | CDK4 known ✓ | P11802 | 12/20 | 1.00 |
| ▸ | CDK1 known ✓ | P06493 | 11/20 | 1.00 |
| ▸ | CDK9 known ✓ | P50750 | 10/20 | 1.00 |
| ▸ | CDK7 known ✓ | P50613 | 3/20 | 1.00 |
| ▸ | CDK6 known ✓ | Q00534 | 2/20 | 1.00 |
| ▸ | CCND1 | P24385 | 11/20 | 1.00 |
| ▸ | CCNB1 | P14635 | 9/20 | 1.00 |
| ▸ | CCNT1 | O60563 | 9/20 | 1.00 |
| ▸ | CCNA2 | P20248 | 8/20 | 1.00 |
| ▸ | CCNB2 | O95067 | 6/20 | 1.00 |
| ▸ | CCNB3 | Q8WWL7 | 6/20 | 1.00 |
| ▸ | CCNE1 | P24864 | 6/20 | 1.00 |
| ▸ | GSK3A | P49840 | 4/20 | 1.00 |
| ▸ | CCNE2 | O96020 | 4/20 | 1.00 |
| ▸ | GSK3B | P49841 | 3/20 | 1.00 |
| ▸ | CCNA1 | P78396 | 3/20 | 1.00 |
| ▸ | PLK4 | O00444 | 2/20 | 1.00 |
| ▸ | PRKD3 | O94806 | 2/20 | 1.00 |
| ▸ | EGFR | P00533 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Alvocidib SCHEMBL29351027 | 1.00 | CDK2 (1.00) | CDK2CDK4CDK1CCND1CDK9 | |
| Alvocidib SCHEMBL29577824 | 1.00 | CDK2 (1.00) | CDK2CDK4CDK1CCND1CDK9 | |
| Alvocidib SCHEMBL12445809 | 1.00 | CDK2 (1.00) | CDK2CDK4CDK1CCND1CDK9 | |
| Alvocidib SCHEMBL29388553 | 1.00 | CDK2 (1.00) | CDK2CDK4CDK1CCND1CDK9 | |
| Alvocidib SCHEMBL3652 | 1.00 | CDK2 (1.00) | CDK2CDK4CDK1CCND1CDK9 | |
| Alvocidib SCHEMBL8214028 | 1.00 | CDK2 (1.00) | CDK2CDK4CDK1CCND1CDK9 | |
| Alvocidib SCHEMBL3651 | 1.00 | CDK2 (1.00) | CDK2CDK4CDK1CCND1CDK9 | |
| Alvocidib SCHEMBL16927354 | 1.00 | CDK2 (1.00) | CDK2CDK4CDK1CCND1CDK9 | |
| Flavopyridol SCHEMBL22580715 | 1.00 | CDK2 (1.00) | CDK2CDK4CDK1CCND1CDK9 | |
| Alvocidib SCHEMBL28199338 | 1.00 | CDK2 (1.00) | CDK2CDK4CDK1CCND1CDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2748331-B1 | SUSCEPTIBILITY TO SELECTIVE CDK9 INHIBITORS | LEAD DISCOVERY CENTER GMBH (DE) | 2016-03-02 | — | — | EP | claimed |
| US-20150329537-A2 | CDK9 INHIBITORS IN THE TREATMENT OF MIDLINE CARCINOMA | LEADDISCOVERY CENTER GMBH (DE) | 2015-11-19 | — | — | US | claimed |
| US-20140303167-A1 | CDK9 INHIBITORS IN THE TREATMENT OF MIDLINE CARCINOMA | LEAD DISCOVERY CENTER GMBH (DE) | 2014-10-09 | — | — | US | claimed |
| US-20140287454-A1 | SUSCEPTIBILITY TO SELECTIVE CDK9 INHIBITORS | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2014-09-25 | — | — | US | claimed |
| EP-2748331-A1 | SUSCEPTIBILITY TO SELECTIVE CDK9 INHIBITORS | Lead Discovery Center GmbH (DE) | 2014-07-02 | — | — | EP | claimed |
| WO-2013026890-A1 | SUSCEPTIBILITY TO SELECTIVE CDK9 INHIBITORS | LEAD DISCOVERY CENTER GMBH (DE) | 2013-02-28 | — | — | WO | claimed |
| EP-2562265-A1 | Susceptibility to selective CDK9 inhibitors | Lead Discovery Center GmbH (DE) | 2013-02-27 | — | — | EP | claimed |
| EP-2561867-A1 | CDK9 inhibitors in the treatment of midline carcinoma | Lead Discovery Center GmbH (DE) | 2013-02-27 | — | — | EP | claimed |
| EP-4393918-A1 | SELF DEGRADATION-TYPE CDK9 INHIBITOR PRODRUG AND LIPOSOME ENCAPSULATING SAME | Sumitomo Pharma Co., Ltd. (JP) | 2024-07-03 | — | — | EP | disclosed |
| EP-4086264-B1 | ALVOCIDIB PRODRUGS HAVING INCREASED BIOAVAILABILITY | SUMITOMO PHARMA ONCOLOGY INC (US) | 2023-10-25 | — | — | EP | disclosed |
| US-11351161-B2 | Use of CDK9 inhibitors to reduce cartilage degradation | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-06-07 | — | — | US | disclosed |
| US-20210277037-A1 | DEUTERATED ALVOCIDIB AND ALVOCIDIB PRODRUGS | SUMITOMO PHARMA ONCOLOGY, INC. | 2021-09-09 | — | — | US | disclosed |
| WO-2021113688-A1 | COMBINATION THERAPIES FOR TREATMENT OF MYELODYSPLASTIC SYNDROME | SUMITOMO DAINIPPON PHARMA ONCOLOGY, INC. (US) | 2021-06-10 | — | — | WO | disclosed |
| US-11020404-B2 | Use of CDK9 and BRD4 inhibitors to inhibit inflammation | The Regents of the University of California, Davis (US) | 2021-06-01 | — | — | US | disclosed |
| WO-2001060367-A1 | COMPOSITIONS COMPRISING FLAVOPIRIDOL AND THEIR USE FOR HIV THERAPY | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2001-08-23 | — | — | WO | disclosed |
| US-20010011076-A1 | COMBINATIONS OF PKC INHIBITORS AND THERAPEUTIC AGENTS FOR TREATING CANCERS | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 2001-08-02 | — | — | US | disclosed |
| US-5908934-A | Process for the preparation of chiral ketone intermediates useful for the preparation of flavopiridol and analogs | BRISTOL-MYERS SQUIBB COMPANY (US) | 1999-06-01 | — | — | US | disclosed |
| EP-0888458-A1 | COMBINATIONS OF PKC INHIBITORS AND THERAPEUTIC AGENTS FOR TREATING CANCERS | Sloan-Kettering Institute For Cancer Research (US) | 1999-01-07 | — | — | EP | disclosed |
| WO-1998013344-A1 | A PROCESS FOR THE PREPARATION OF CHIRAL KETONE INTERMEDIATES USEFUL FOR THE PREPARATION OF FLAVOPIRIDOL AND ANALOGS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-04-02 | — | — | WO | disclosed |
| WO-1997030174-A1 | COMBINATIONS OF PKC INHIBITORS AND THERAPEUTIC AGENTS FOR TREATING CANCERS | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 1997-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010011076-A1 | COMBINATIONS OF PKC INHIBITORS AND THERAPEUTIC AGENTS FOR TREATING CANCERS | PRKCI, PRKCA, PRKCH | CDK2 326/4885CDK4 310/4885CDK1 314/4885 |
| US-11020404-B2 | Use of CDK9 and BRD4 inhibitors to inhibit inflammation | CDK9, BRD4, CDK19 | CDK2 11/4885CDK4 9/4885CDK1 14/4885 |
| US-20150329537-A2 | CDK9 INHIBITORS IN THE TREATMENT OF MIDLINE CARCINOMA | CDK9, CDK19, CDKN1A | CDK2 27/4885CDK4 8/4885CDK1 4/4885 |
| US-20210277037-A1 | DEUTERATED ALVOCIDIB AND ALVOCIDIB PRODRUGS | CDK4, CDK11B, CDK3 | CDK2 9/4885CDK4 1/4885CDK1 4/4885 |
| US-11351161-B2 | Use of CDK9 inhibitors to reduce cartilage degradation | CDK9, CDK19, CDKN1A | CDK2 8/4885CDK4 18/4885CDK1 7/4885 |
| US-20140303167-A1 | CDK9 INHIBITORS IN THE TREATMENT OF MIDLINE CARCINOMA | CDK9, CDK19, CDKN1A | CDK2 27/4885CDK4 8/4885CDK1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.